Medication Intake 24 Hours Before 18F-FDG Administration
| Medication | No. of patients (% total study population) |
|---|---|
| β-Blockers | 104 (21) |
| Angiotensin-converting enzyme inhibitors | 74 (15) |
| Vitamins and minerals | 69 (14) |
| Statins (cholesterol-lowering agents) | 65 (13) |
| Aspirin | 63 (13) |
| Ca-channel blockers | 57 (11) |
| Omeprazole (proton pump inhibitors) | 56 (11) |
| Oral antidiabetic | 53 (11) |
| Benzodiazepines (central nervous system depressants) | 45 (9) |
| Levothyroxine (thyroid replacement drug) | 40 (8) |
| Diuretics | 38 (8) |
| Antipyretics | 33 (7) |
| α-Blockers | 27 (5) |
| Warfarin (anticoagulant) | 23 (5) |
| Antibiotics | 21 (4) |
| Estrogen/progesterone compounds | 18 (4) |
| Bronchodilators | 15 (3) |
| Antidepressive | 15 (3) |
| Allopurinol (xanthine oxidase inhibitor or antigout) | 13 (3) |
| Selective serotonin reuptake inhibitors | 13 (3) |
| Nitrates | 13 (3) |
| Insulin | 13 (3) |
| Antacids (H2 blockers) | 13 (3) |
| Nonsteroidal antiinflammatory drugs | 12 (2) |
| Antiarrhythmic (excluding β-blockers and Ca-channel blockers) | 12 (2) |
| Opioids | 11 (2) |
| Bezafibrate (lipid-lowering agent) | 11 (2) |
| Steroids | 10 (2) |
| Antiepileptics (excluding benzodiazepines) | 9 (2) |
Three hundred twenty-nine patients received concurrent medications.